iRadimed Corporation (IRMD) Rating Increased to Hold at ValuEngine

ValuEngine upgraded shares of iRadimed Corporation (NASDAQ:IRMD) from a sell rating to a hold rating in a research note released on Friday.

A number of other analysts have also commented on IRMD. TheStreet upgraded iRadimed Corporation from a d rating to a c- rating in a report on Friday, June 23rd. Roth Capital upgraded iRadimed Corporation from a neutral rating to a buy rating and boosted their target price for the company from $9.00 to $12.00 in a research note on Monday, July 31st. Finally, Zacks Investment Research upgraded iRadimed Corporation from a hold rating to a buy rating and set a $11.00 target price on the stock in a research note on Friday, August 4th.

Shares of iRadimed Corporation (NASDAQ:IRMD) opened at 10.275 on Friday. iRadimed Corporation has a 1-year low of $7.85 and a 1-year high of $14.24. The company has a 50-day moving average price of $9.97 and a 200-day moving average price of $9.05. The company has a market cap of $108.73 million, a PE ratio of 42.992 and a beta of 1.48.

iRadimed Corporation (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, July 28th. The medical equipment provider reported $0.06 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.07. The business had revenue of $5.50 million for the quarter, compared to analyst estimates of $5.41 million. iRadimed Corporation had a return on equity of 8.98% and a net margin of 11.61%. iRadimed Corporation’s quarterly revenue was down 44.4% compared to the same quarter last year. During the same period last year, the company posted $0.24 earnings per share. Equities research analysts expect that iRadimed Corporation will post $0.13 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “iRadimed Corporation (IRMD) Rating Increased to Hold at ValuEngine” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://ledgergazette.com/2017/10/10/iradimed-corporation-irmd-rating-increased-to-hold-at-valuengine.html.

Institutional investors and hedge funds have recently modified their holdings of the business. Neuberger Berman Group LLC bought a new stake in shares of iRadimed Corporation in the first quarter valued at $134,000. Citigroup Inc. raised its stake in shares of iRadimed Corporation by 50.8% in the second quarter. Citigroup Inc. now owns 16,082 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 5,418 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of iRadimed Corporation in the first quarter valued at $290,000. Connors Investor Services Inc. raised its stake in shares of iRadimed Corporation by 10.0% in the second quarter. Connors Investor Services Inc. now owns 33,000 shares of the medical equipment provider’s stock valued at $284,000 after buying an additional 3,000 shares during the period. Finally, Federated Investors Inc. PA raised its stake in shares of iRadimed Corporation by 7.5% in the second quarter. Federated Investors Inc. PA now owns 40,400 shares of the medical equipment provider’s stock valued at $347,000 after buying an additional 2,807 shares during the period. Hedge funds and other institutional investors own 14.19% of the company’s stock.

About iRadimed Corporation

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, an

A number of other analysts have also commented on IRMD. TheStreet upgraded iRadimed Corporation from a d rating to a c- rating in a report on Friday, June 23rd. Roth Capital upgraded iRadimed Corporation from a neutral rating to a buy rating and boosted their target price for the company from $9.00 to $12.00 in a research note on Monday, July 31st. Finally, Zacks Investment Research upgraded iRadimed Corporation from a hold rating to a buy rating and set a $11.00 target price on the stock in a research note on Friday, August 4th.

Shares of iRadimed Corporation (NASDAQ:IRMD) opened at 10.275 on Friday. iRadimed Corporation has a 1-year low of $7.85 and a 1-year high of $14.24. The company has a 50-day moving average price of $9.97 and a 200-day moving average price of $9.05. The company has a market cap of $108.73 million, a PE ratio of 42.992 and a beta of 1.48.

iRadimed Corporation (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, July 28th. The medical equipment provider reported $0.06 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.07. The business had revenue of $5.50 million for the quarter, compared to analyst estimates of $5.41 million. iRadimed Corporation had a return on equity of 8.98% and a net margin of 11.61%. iRadimed Corporation’s quarterly revenue was down 44.4% compared to the same quarter last year. During the same period last year, the company posted $0.24 earnings per share. Equities research analysts expect that iRadimed Corporation will post $0.13 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “iRadimed Corporation (IRMD) Rating Increased to Hold at ValuEngine” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://ledgergazette.com/2017/10/10/iradimed-corporation-irmd-rating-increased-to-hold-at-valuengine.html.

Institutional investors and hedge funds have recently modified their holdings of the business. Neuberger Berman Group LLC bought a new stake in shares of iRadimed Corporation in the first quarter valued at $134,000. Citigroup Inc. raised its stake in shares of iRadimed Corporation by 50.8% in the second quarter. Citigroup Inc. now owns 16,082 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 5,418 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of iRadimed Corporation in the first quarter valued at $290,000. Connors Investor Services Inc. raised its stake in shares of iRadimed Corporation by 10.0% in the second quarter. Connors Investor Services Inc. now owns 33,000 shares of the medical equipment provider’s stock valued at $284,000 after buying an additional 3,000 shares during the period. Finally, Federated Investors Inc. PA raised its stake in shares of iRadimed Corporation by 7.5% in the second quarter. Federated Investors Inc. PA now owns 40,400 shares of the medical equipment provider’s stock valued at $347,000 after buying an additional 2,807 shares during the period. Hedge funds and other institutional investors own 14.19% of the company’s stock.

About iRadimed Corporation

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for iRadimed Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply